Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 3/20 | 0.43 |
| ▸ | TTR | P02766 | 2/20 | 0.41 |
| ▸ | ALB | P02768 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | HPGDS | O60760 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.36 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.36 |
| ▸ | EGFR | P00533 | 1/20 | 0.35 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.34 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.34 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.34 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25198419 | 0.88 | AR (0.45) | ARTTRALBMEN1KMT2A | |
| SCHEMBL523635 | 0.79 | TSHR (0.46) | ARTTRALBMEN1KMT2A | |
| SCHEMBL26094739 | 0.79 | KDM4E (0.42) | POLBKDM4EUSP2ALDH1A1MAPT | |
| SCHEMBL31432665 | 0.79 | AR (0.44) | ARTTRALBKMT2AHPGDS | |
| SCHEMBL6644614 | 0.79 | AR (0.49) | ARTTRALBMEN1KMT2A | |
| SCHEMBL509507 | 0.79 | ACHE (0.52) | ARL3MBTL1KDM4EALDH1A1MAPT | |
| SCHEMBL18112970 | 0.78 | MEN1 (0.44) | ARTTRALBMEN1KMT2A | |
| SCHEMBL31038036 | 0.78 | TTR (0.44) | ARTTRALBMEN1KMT2A | |
| SCHEMBL31014083 | 0.78 | XDH (0.36) | ARTTRALBMEN1KMT2A | |
| SCHEMBL18585500 | 0.78 | MAPT (0.48) | ARTTRALBMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190328706-A1 | COMPOSITIONS COMPRISING AN INTEGRIN INHIBITOR AND AGENTS WHICH INTERACT WITH A CHEMOKINE AND METHODS OF USE THEREOF | SAINT LOUIS UNIVERSITY | 2019-10-31 | — | — | US | disclosed |
| US-20190328706-A1 | COMPOSITIONS COMPRISING AN INTEGRIN INHIBITOR AND AGENTS WHICH INTERACT WITH A CHEMOKINE AND METHODS OF USE THEREOF | SAINT LOUIS UNIVERSITY | 2019-10-31 | — | — | US | disclosed |
| US-8530504-B2 | Pyrazolothiazole compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-09-10 | — | — | US | disclosed |
| US-8530504-B2 | Pyrazolothiazole compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-09-10 | — | — | US | disclosed |
| US-8530504-B2 | Pyrazolothiazole compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-09-10 | — | — | US | disclosed |
| US-8431603-B2 | 3-phenylpyrazolo[5,1-b]thiazole compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-04-30 | — | — | US | disclosed |
| US-8431603-B2 | 3-phenylpyrazolo[5,1-b]thiazole compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-04-30 | — | — | US | disclosed |
| US-8431603-B2 | 3-phenylpyrazolo[5,1-b]thiazole compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-04-30 | — | — | US | disclosed |
| EP-2266990-B1 | 3-PHENYLPYRAZOLO[5,1-b]THIAZOLE COMPOUND | EISAI R&D MAN CO LTD (JP) | 2012-09-26 | — | — | EP | disclosed |
| EP-2266990-B1 | 3-PHENYLPYRAZOLO[5,1-b]THIAZOLE COMPOUND | EISAI R&D MAN CO LTD (JP) | 2012-09-26 | — | — | EP | disclosed |
| US-20090259049-A1 | 3-PHENYLPYRAZOLO[5,1-b]THIAZOLE COMPOUNDS | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2009-10-15 | — | — | US | disclosed |
| US-20090259049-A1 | 3-PHENYLPYRAZOLO[5,1-b]THIAZOLE COMPOUNDS | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2009-10-15 | — | — | US | disclosed |
| US-20080242884-A1 | Process for Preparing Nitriles by Elimination Reactions | EUTICALS GMBH (DE) | 2008-10-02 | — | — | US | disclosed |
| EP-1701933-B1 | NOVEL COMPOUNDS | MITSUBISHI TANABE PHARMA CORP (JP) | 2008-09-03 | — | — | EP | disclosed |
| CN-101208296-A | Process for preparing nitriles by elimination reactions | ARCHIMICA GMBH (DE) | 2008-06-25 | — | — | CN | disclosed |
| EP-1910276-A1 | PROCESS FOR PREPARING NITRILES BY ELIMINATION REACTIONS | Archimica GmbH (DE) | 2008-04-16 | — | — | EP | disclosed |
| US-20070043113-A1 | Novel compounds | TANABE SEIYAKU CO., LTD. (JP) | 2007-02-22 | — | — | US | disclosed |
| WO-2007012387-A1 | PROCESS FOR PREPARING NITRILES BY ELIMINATION REACTIONS | ARCHIMICA GMBH (DE) | 2007-02-01 | — | — | WO | disclosed |
| EP-1701933-A1 | NOVEL COMPOUNDS | TANABE SEIYAKU CO., LTD. (JP) | 2006-09-20 | — | — | EP | disclosed |
| WO-2005061440-A1 | NOVEL COMPOUNDS | TANABE SEIYAKU CO., LTD. (JP) | 2005-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190328706-A1 | COMPOSITIONS COMPRISING AN INTEGRIN INHIBITOR AND AGENTS WHICH INTERACT WITH A CHEMOKINE AND METHODS OF USE THEREOF | CXCL12, CXCR4, SDF4 | AR 2041/4885TTR 2343/4885ALB 2792/4885 |
| US-20080242884-A1 | Process for Preparing Nitriles by Elimination Reactions | CBR1, CBR3, PHOSPHO1 | AR 1281/4885TTR 1232/4885ALB 3438/4885 |
| US-20090259049-A1 | 3-PHENYLPYRAZOLO[5,1-b]THIAZOLE COMPOUNDS | CRHR1, AGTR1, CRHR2 | AR 338/4885TTR 2643/4885ALB 2944/4885 |
| US-20070043113-A1 | Novel compounds | VCAM1, ICAM1, EPCAM | AR 4577/4885TTR 668/4885ALB 1383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.